Health Care Innovation
Business & Economics
Rising Regulatory Burdens, Declining Health Outcomes
Tweaks do not turn bad regulatory proposals into good ones. Yet, with only minor modifications, Congress is once again considering the CREATES Act (Creating and Restoring Equal Access to Equivalent Samples Act of 2017), and its close cousin, the FAST Act (Fair Access for Safe and Timely Generics Act of ...
Business & Economics
New Study Finds High Prescription Drug Costs Are Not Driving Up U.S. Healthcare Costs
It’s easy for politicians and consumers to rage about the high price of prescription drugs, but Wayne Winegarden, Pacific Research Institute’s senior fellow in business and economics, said those prices are not to blame for the high cost of healthcare in the United States. Recently, U.S. Bernie Sanders has been ...
Business & Economics
Drug Importation Will Not Improve Health Care Affordability
The growing problem of health care affordability requires prompt and effective policy solutions. However, just as the wrong medical diagnosis will not cure a patient, and may make the patient even sicker, the wrong policy solution will not address the U.S. health care affordability problem, and may even worsen the ...
Business & Economics
New PRI Study Finds That High Prescription Drug Costs Are Not Driving Up U.S. Health Care Costs
A more realistic evaluation of U.S. prescription drug prices shows that high drug prices are not actually driving up health care costs overall, and reflect the higher U.S. health care costs compared to the rest of the world, according to a new report released today by the Pacific Research Institute. ...
Drug Innovation
ISSUE BRIEF: Nevada Proposal To Regulate Excess Costs Are Price Controls By Another Name
Click here to download a copy of PRI’s Issue Brief Senate Bill 265 would require pharmaceutical firms to reimburse insurers for any “excess costs” associated with drugs for diabetes, which are defined as the excess costs over the highest price in other developed countries. The Fiscal Notes on SB 265 ...
Commentary
The Good, The Bad, And The NICE: A Cautionary Tale For Government Negotiation
One of the cornerstones of Great Britain’s National Health Service is an agency that approves and controls access to prescription drugs, the National Institute for Health and Care Excellence. NICE recently announced a new policy that could delay and restrict access to new medicines for British citizens if the agency ...
California
Single Payer Is Fool’s Gold For California
While the latest Republican attempt to repeal and replace ObamaCare may have failed, Democrats in California and in D.C. are just getting started in their effort to eliminate the health law. Unfortunately, they’re angling to replace ObamaCare with something even worse. In California, State Senators Ricardo Lara and Toni Atkins ...
California
California Single-Payer Bill Looks Backward, Instead Of Forward To A New Era Of Patient Choice
Here we go again. The California State Legislature is considering yet another bill to impose a so-called single-payer, government monopoly, health care system. This has long been an obsession of the California’s nurses unions, because a health system under total government control would suit the narrow interests of union leaders. ...
Commentary
Oregon’s Drug Price Bill Is Hard To Swallow
President Donald Trump is not the only politician saying he is going to work to get drug prices down. Oregon lawmakers are already patting themselves on the back for tackling drug prices. Rep. Mitch Greenlick (D-Portland) says the measure, Oregon House Bill 2387, could be a model for national reform. ...
Drug Innovation
ISSUE BRIEF: Oregon Proposal To Regulate Excess Costs Is Price Controls By Another Name
Introduced in February, HB 2387 would require pharmaceutical firms to reimburse insurers for any “excess costs” associated with covered drugs. Excess costs are defined as the difference between the average wholesale price of a drug and either: the typical price in other countries; or, the difference between a health plan’s ...
Rising Regulatory Burdens, Declining Health Outcomes
Tweaks do not turn bad regulatory proposals into good ones. Yet, with only minor modifications, Congress is once again considering the CREATES Act (Creating and Restoring Equal Access to Equivalent Samples Act of 2017), and its close cousin, the FAST Act (Fair Access for Safe and Timely Generics Act of ...
New Study Finds High Prescription Drug Costs Are Not Driving Up U.S. Healthcare Costs
It’s easy for politicians and consumers to rage about the high price of prescription drugs, but Wayne Winegarden, Pacific Research Institute’s senior fellow in business and economics, said those prices are not to blame for the high cost of healthcare in the United States. Recently, U.S. Bernie Sanders has been ...
Drug Importation Will Not Improve Health Care Affordability
The growing problem of health care affordability requires prompt and effective policy solutions. However, just as the wrong medical diagnosis will not cure a patient, and may make the patient even sicker, the wrong policy solution will not address the U.S. health care affordability problem, and may even worsen the ...
New PRI Study Finds That High Prescription Drug Costs Are Not Driving Up U.S. Health Care Costs
A more realistic evaluation of U.S. prescription drug prices shows that high drug prices are not actually driving up health care costs overall, and reflect the higher U.S. health care costs compared to the rest of the world, according to a new report released today by the Pacific Research Institute. ...
ISSUE BRIEF: Nevada Proposal To Regulate Excess Costs Are Price Controls By Another Name
Click here to download a copy of PRI’s Issue Brief Senate Bill 265 would require pharmaceutical firms to reimburse insurers for any “excess costs” associated with drugs for diabetes, which are defined as the excess costs over the highest price in other developed countries. The Fiscal Notes on SB 265 ...
The Good, The Bad, And The NICE: A Cautionary Tale For Government Negotiation
One of the cornerstones of Great Britain’s National Health Service is an agency that approves and controls access to prescription drugs, the National Institute for Health and Care Excellence. NICE recently announced a new policy that could delay and restrict access to new medicines for British citizens if the agency ...
Single Payer Is Fool’s Gold For California
While the latest Republican attempt to repeal and replace ObamaCare may have failed, Democrats in California and in D.C. are just getting started in their effort to eliminate the health law. Unfortunately, they’re angling to replace ObamaCare with something even worse. In California, State Senators Ricardo Lara and Toni Atkins ...
California Single-Payer Bill Looks Backward, Instead Of Forward To A New Era Of Patient Choice
Here we go again. The California State Legislature is considering yet another bill to impose a so-called single-payer, government monopoly, health care system. This has long been an obsession of the California’s nurses unions, because a health system under total government control would suit the narrow interests of union leaders. ...
Oregon’s Drug Price Bill Is Hard To Swallow
President Donald Trump is not the only politician saying he is going to work to get drug prices down. Oregon lawmakers are already patting themselves on the back for tackling drug prices. Rep. Mitch Greenlick (D-Portland) says the measure, Oregon House Bill 2387, could be a model for national reform. ...
ISSUE BRIEF: Oregon Proposal To Regulate Excess Costs Is Price Controls By Another Name
Introduced in February, HB 2387 would require pharmaceutical firms to reimburse insurers for any “excess costs” associated with covered drugs. Excess costs are defined as the difference between the average wholesale price of a drug and either: the typical price in other countries; or, the difference between a health plan’s ...
